A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
复制标题
DOI：
10.1111/dom.12262
复制
发表时间：
2014-07-01
影响因子：
5.8
通讯作者：
Zinman, B.
中科院分区：
文献类型：
--
作者：
Mathieu, C.;Rodbard, H. W.;Zinman, B.
目的：在需要强化的基础胰岛素治疗的2型糖尿病（T2 DM）患者中比较了两种治疗策略：在最大进餐量的情况下添加每日一次（OD）利拉鲁肽（里拉）或OD门冬胰岛素（IAsp）。完成104周的受试者（52周主试验开始ONCE-LONG + 52周扩展）接受德谷胰岛素（IDeg）OD +二甲双胍治疗，HbA 1c ≥ 7.0%（>= 53 mmol/mol）随机分配至IDeg+里拉[n=88，平均HbA 1c：7.7%（61 mmol/mol）]或IDeg+IAsp（n=89，平均HbA 1c：7.7%），持续26周，继续二甲双胍治疗。完成104周且HbA 1c的受试者
Aim: Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification: addition of once-daily (OD) liraglutide (Lira) or OD insulin aspart (IAsp) with largest meal.Methods: Subjects completing 104 weeks (52-week main trial BEGIN ONCE-LONG + 52-week extension) on insulin degludec (IDeg) OD + metformin with HbA1c >= 7.0% (>= 53 mmol/mol) were randomized to IDeg+Lira [n=88, mean HbA1c: 7.7% (61 mmol/mol)] or IDeg+IAsp (n=89, mean HbA1c: 7.7%) for 26 weeks, continuing metformin. Subjects completing 104 weeks with HbA1c